MARLBOROUGH, Mass., April 8, 2022 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today presented positive new preclinical … Continue reading Phio Pharmaceuticals (NASDAQ: PHIO) Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022